Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Repetition (doing the same thing repeatedly) is essential for learning and mastering new skills. Task repetition is a key to transforming short-term memories into long-term memories. Repetition is ...

Portrait photography is one of the most rewarding yet challenging genres to master. It demands technical ability, a sensitivity to light and, perhaps most importantly, an ability to connect with the ...

The David Rubenstein Show: Peer-to-Peer Conversations" explores successful leadership through the personal and professional choices of the most influential people in business.

So, you want to get better at LeetCode using JavaScript? It can feel like a big mountain to climb at first, especially when you see all the problems and don’t know where to start. Lots of people feel ...

JavaScript is a sprawling and ever-changing behemoth, and may be the single-most connective piece of web technology. From AI to functional programming, from the client to the server, here are nine ...

Alphabet Inc.'s (NASDAQ:GOOG) (NASDAQ:GOOGL) Isomorphic Labs says its first artificial-intelligence-designed medicines are nearly ready for human testing. What Happened: Isomorphic Labs President ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...